Cabozantinib and dastinib exert anti-tumor activity in alveolar soft part sarcoma.

Kenta MukaiharaYu TanabeDaisuke KubotaKeisuke AkaikeTakuo HayashiKaoru MogushiMasaki HosoyaShingo SatoEisuke KobayashiTaketo OkuboYoungji KimShinji KohsakaTsuyoshi SaitoKazuo KanekoYoshiyuki Suehara

Published in: PloS one (2017)

Our findings suggest that cabozantinib and dasatinib may be more effective than pazopanib against ASPS cells. These in vitro and in vivo data suggest that c-MET may be a potential therapeutic target in ASPS, and cabozantinib may be a particularly useful therapeutic option for patients with ASPS, including those with pazopanib-resistant ASPS.

Keyphrases

metastatic renal cell carcinoma
induced apoptosis
cell cycle arrest
electronic health record
tyrosine kinase
big data
oxidative stress
machine learning
risk assessment
data analysis